Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Matinas is a clinical-stage biopharmaceutical company focused on its Lipid Nanocrystal (LNC) platform. Its lead product candidate is MAT2203 (oral amphotericin B), an antifungal drug. Following the termination of partnership negotiations in October 2024, the Company implemented an 80% workforce reduction, paused clinical development of MAT2203, and is currently seeking a strategic partner or additional capital to advance the product to Phase 3.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10.3) million | $(24.3) million |
| Operating Expenses | $7.0 million | $24.6 million |
| Research & Development | $0.1 million | $11.4 million |
| General & Administrative | $6.9 million | $8.7 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $4.0 million | $7.3 million |
| Accumulated Deficit | $(210.8) million | $(199.8) million |
| Outstanding Common Shares (Mar 26, 2026) | 6,406,191 | N/A |
Note: All financial figures are in thousands unless otherwise noted. The filing text does not provide specific margin data as the Company has no revenue.
Material Changes vs. Prior Period
- Significant Reduction in Expenses: Total operating expenses decreased by approximately 72% from $24.6 million in 2024 to $7.0 million in 2025. This was driven primarily by an 80% workforce reduction in late 2024 and the subsequent pause in clinical development activities.
- Research and Development (R&D): R&D expenses plummeted from $11.4 million in 2024 to $0.1 million in 2025 due to the cessation of clinical trial activities and manufacturing process development.
- Impairment Charges: In 2024, the Company recorded $4.4 million in impairment charges (goodwill, IPR&D, and other assets) following the failed partnership negotiations. No impairment charges were recorded in 2025.
- Capital Raises: In 2025, the Company raised approximately $3.3 million through a private placement of Series C Convertible Preferred Stock and warrants. In 2024, the Company raised approximately $10 million via a registered direct offering.
- Stock Structure: The Company executed a 1-for-50 reverse stock split in August 2024. In 2025, shareholders approved an increase in authorized common shares from 250 million to 500 million.
Guidance, Outlook, and Risks
Outlook and Strategy
The Company's primary strategy is to secure a development or commercialization partner for MAT2203 to fund the Phase 3 ORALTO trial. Management does not believe existing cash resources ($4.0 million) are sufficient to fund operations beyond the next twelve months. The Company is actively evaluating strategic alternatives, including a potential winddown or dissolution if a partnership or capital raise is not successful.
Going Concern
The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern. The financial statements do not include adjustments that might result from the outcome of this uncertainty.
Key Risks and Contingencies
- Liquidity Risk: Immediate need for additional funding to avoid insolvency or dissolution.
- Partnership Uncertainty: No assurance that a transaction involving MAT2203 will be consummated.
- Legal Proceedings: The Company is involved in litigation with its landlord (COE Bridgewater, LLC) regarding an alleged illegal lockout of its Bridgewater, NJ facility. The landlord seeks approximately $205,000 in unpaid rent and damages.
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting in 2024 related to non-routine transactions. Management believes this was remediated in 2025.
- Listing Compliance: The Company previously faced NYSE American compliance issues regarding stock price and annual meeting requirements, which were resolved in 2025.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to confirm the timeline for potential insolvency or need for emergency financing.
- Partnership Status: Confirm if any definitive agreements have been signed with potential partners for MAT2203 since the filing date.
- Legal Resolution: Monitor the status of the lease dispute with COE Bridgewater, LLC, as a loss could further deplete cash reserves.
- Capital Structure: Review the terms of the Series C Convertible Preferred Stock and outstanding warrants, noting the significant dilution potential upon conversion or exercise.
- Regulatory Status: Confirm the status of the MAT2203 Investigational New Drug (IND) application with the FDA to ensure it remains active.